3.8(top 10%)
impact factor
498(top 50%)
papers
7.8K(top 20%)
citations
40(top 20%)
h-index
3.9(top 10%)
impact factor
733
all documents
8.7K
doc citations
58(top 20%)
g-index

Top Articles

#TitleJournalYearCitations
1Gender differences in the effects of cardiovascular drugsEuropean Heart Journal - Cardiovascular Pharmacotherapy2017204
2ESC Council on hypertension position document on the management of hypertensive emergenciesEuropean Heart Journal - Cardiovascular Pharmacotherapy2019155
3Statin therapy in COVID-19 infectionEuropean Heart Journal - Cardiovascular Pharmacotherapy2020154
4Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of CardiologyEuropean Heart Journal - Cardiovascular Pharmacotherapy2018113
5Anticoagulation in COVID-19European Heart Journal - Cardiovascular Pharmacotherapy2020105
6PCSK9 and inflammation: a review of experimental and clinical evidenceEuropean Heart Journal - Cardiovascular Pharmacotherapy2019104
7Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGEREuropean Heart Journal - Cardiovascular Pharmacotherapy201699
8A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulantsEuropean Heart Journal - Cardiovascular Pharmacotherapy201793
9Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarctionEuropean Heart Journal - Cardiovascular Pharmacotherapy201573
10Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectivesEuropean Heart Journal - Cardiovascular Pharmacotherapy201773
11A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockersEuropean Heart Journal - Cardiovascular Pharmacotherapy202172
12Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patientsEuropean Heart Journal - Cardiovascular Pharmacotherapy202069
13The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarctionEuropean Heart Journal - Cardiovascular Pharmacotherapy202169
14Melatonin has multiorgan effectsEuropean Heart Journal - Cardiovascular Pharmacotherapy201664
15Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patientsEuropean Heart Journal - Cardiovascular Pharmacotherapy202264
16Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case–time–control studyEuropean Heart Journal - Cardiovascular Pharmacotherapy201763
17Pharmacotherapy for coronary microvascular dysfunctionEuropean Heart Journal - Cardiovascular Pharmacotherapy201561
18A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery diseaseEuropean Heart Journal - Cardiovascular Pharmacotherapy201661
19Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysisEuropean Heart Journal - Cardiovascular Pharmacotherapy201961
20The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational studyEuropean Heart Journal - Cardiovascular Pharmacotherapy202161
21Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trialEuropean Heart Journal - Cardiovascular Pharmacotherapy201559
22Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort studyEuropean Heart Journal - Cardiovascular Pharmacotherapy202059
23Cardiovascular safety of anti-diabetic drugsEuropean Heart Journal - Cardiovascular Pharmacotherapy201656
24New oral anticoagulants: a practical guide for physiciansEuropean Heart Journal - Cardiovascular Pharmacotherapy201554
25The current role and future prospects of D-dimer biomarkerEuropean Heart Journal - Cardiovascular Pharmacotherapy201652
26Differential epigenetic factors in the prediction of cardiovascular risk in diabetic patientsEuropean Heart Journal - Cardiovascular Pharmacotherapy202052
27Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortalityEuropean Heart Journal - Cardiovascular Pharmacotherapy202051
28Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillationEuropean Heart Journal - Cardiovascular Pharmacotherapy202151
29Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registriesEuropean Heart Journal - Cardiovascular Pharmacotherapy201650
30Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)European Heart Journal - Cardiovascular Pharmacotherapy201750
31Left ventricular thrombosis: new perspectives on an old problemEuropean Heart Journal - Cardiovascular Pharmacotherapy202150
32Interleukin-1 blockade for the treatment of pericarditisEuropean Heart Journal - Cardiovascular Pharmacotherapy201849
33Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian settingEuropean Heart Journal - Cardiovascular Pharmacotherapy201848
34Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?European Heart Journal - Cardiovascular Pharmacotherapy202048
35Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2scoreEuropean Heart Journal - Cardiovascular Pharmacotherapy201547
36Non-vitamin-K oral anticoagulants and laboratory testing: now and in the futureEuropean Heart Journal - Cardiovascular Pharmacotherapy201747
37P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registriesEuropean Heart Journal - Cardiovascular Pharmacotherapy201646
38Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on StrokeEuropean Heart Journal - Cardiovascular Pharmacotherapy201946
39An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcomeEuropean Heart Journal - Cardiovascular Pharmacotherapy202046
40Association between renin–angiotensin system inhibitors and COVID-19 complicationsEuropean Heart Journal - Cardiovascular Pharmacotherapy202146
41Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonistsEuropean Heart Journal - Cardiovascular Pharmacotherapy201745
42Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patientsEuropean Heart Journal - Cardiovascular Pharmacotherapy202145
43Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trialsEuropean Heart Journal - Cardiovascular Pharmacotherapy202245
44Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challengeEuropean Heart Journal - Cardiovascular Pharmacotherapy201944
45Advocating cardiovascular precision medicine with P2Y12 receptor inhibitorsEuropean Heart Journal - Cardiovascular Pharmacotherapy201743
46The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin–angiotensin systemEuropean Heart Journal - Cardiovascular Pharmacotherapy202042
47Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance databaseEuropean Heart Journal - Cardiovascular Pharmacotherapy202142
48The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agentEuropean Heart Journal - Cardiovascular Pharmacotherapy201641
49Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patientsEuropean Heart Journal - Cardiovascular Pharmacotherapy202041
50Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)European Heart Journal - Cardiovascular Pharmacotherapy201640